NTRK1 and meningioma: Notably, nine of the 10 drugs primarily target kinases and receptor tyrosine kinases (RTK) (with the exception of mitoxantrone that targets topoisomerase) thus highlighting kinases as potential therapeutic targets within VS and meningioma amenable to drug repurposing.